

## **Herbal Remedies in Global Healthcare: Classification, Toxicology, and Clinical Management**

Vanessa Steenkamp<sup>\*,^</sup>, Hafiza Parkar<sup>\*</sup>, Boitumelo Raphiri<sup>\*</sup>, Manuela G. Neuman and  
Amitava Dasgupta <sup>#, @</sup>

<sup>\*</sup>Department of Pharmacology, Faculty of Health Sciences, University of Pretoria

<sup>#</sup>Department of Pathology and Laboratory Medicine, University of Kansas Medical Center,  
Kansas City, KS, USA

<sup>@</sup> In Vitro Drug Safety and Biotechnology, Department of Pharmacology and Toxicology,  
Temerity Faculty of Medicine, Toronto, Ontario, Canada

<sup>^</sup>Address for correspondence and reprints:

Prof V. Steenkamp

Department of Pharmacology

Faculty of Health Sciences

University of Pretoria

Private bag X323

Arcadia

South Africa

0001

Tel: +27-12-319-2109

e-mail: [vanessa.steenkamp@up.ac.za](mailto:vanessa.steenkamp@up.ac.za)

## **Abstract**

**Background:** Traditional herbal medicines are crucial in the health care system worldwide, particularly for individuals with chronic illnesses. These remedies are commonly classified by purpose, composition, mechanism of action, and origin, with the World Health Organization outlining 4 main categories: indigenous herbal medicines, those used in traditional systems, modified herbal medicines, and imported herbal products. The authors explored the toxicology of commonly used herbal remedies, including their mechanisms, signs and symptoms of toxicity, and treatment strategies.

**Methods:** Literature was searched using different published resources and databases, PubMed and ScienceDirect. The searched terms included “herbal medicine,” “herbal remedies,” “traditional medicine systems,” “herbal toxicity,” “herbal toxicity mechanism of action/toxicity,” among others. The searches were limited to the English language, with no restrictions on publication date.

**Results:** The perception that herbal medicines are inherently safe is misleading. Herbal remedies can be toxic due to the plant's intrinsic properties or through contamination and adulteration. Moreover, 15%–20% of individuals on prescription drugs concurrently use herbal supplements, increasing the risk of harmful interactions. Incidence of herb-induced toxicities, particularly hepatotoxicity, is related to the use of Kava, Chaparral, Comfrey, Germander, and green tea extract. Moreover, cardiovascular toxicity due to Chan Su and oleander-containing herbal remedy use is detected by assessing serum digoxin concentration and is treated with Digibind. Although advances in modern formulations and increased regulatory oversight have improved safety, shortcomings remain, particularly in public awareness and standardized regulations.

**Conclusion:** Comprehensive clinical management, patient education, and integration of traditional medicine into mainstream health care ensures safe, effective, and responsible use of herbal products.

**Keywords:** herbal remedies, traditional medicine, traditional medicine systems, herbal toxicity

## **Introduction**

The World Health Organization (WHO) defines traditional medicine as the sum of knowledge, skills, and practices, based on theories, beliefs, and experiences from different cultures, used to maintain health and prevent, diagnose, improve, or treat illnesses. This term includes plant-, animal-, and mineral-based medicines, spiritual therapies, and manual or exercise-based techniques applied singly or in combination to promote well-being.<sup>1</sup>

Similar to most medications, herbal remedies have been classified. The classification is based on numerous factors, such as their purpose (medicinal versus supplemental), chemical composition and additives, mechanism of action, plant origin, and parts used (leaves versus roots). The classification system was introduced by the WHO in 2003.<sup>2</sup> There are four different herbal remedies categories (i) Indigenous herbal medicines (ii) Herbal medicines in systems (iii) Modified herbal medicines and (iv) Imported products with a herbal medicine base.

Indigenous herbal medicines are traditionally used within specific communities or regions, and their composition, methods of use, and dosages are determined by long-standing cultural practices. Although formal documentation is often limited, these methods are widely accepted and used locally. However, once introduced to broader markets, they must comply with national safety and efficacy regulations. In contrast, herbal medicines from established traditional systems, such as Ayurveda, Unani, and Siddha, are well-documented and grounded in recognized theoretical frameworks endorsed by national authorities. Modified herbal medicines, which originate from traditional remedies but have undergone changes in formulation, dosage, or method of administration, must meet regulatory standards. Imported herbal products, whether raw materials or finished goods, must first be approved in their country of origin and adhere to the safety and efficacy requirements of the importing nation.<sup>3</sup>

Herbal remedies are classified according to their actions and the extent to which they affect different physiological systems within the body. They are classified as sedatives, antiseptics, or diuretics.<sup>4</sup>

The global herbal medicine market was valued at USD 148.5 billion in 2022 and is projected to reach USD 368.07 billion by 2032. This growth reflects the increasing consumer confidence

in herbal remedies as alternatives to conventional pharmaceuticals. Contributing factors include perceptions of greater effectiveness and relative affordability of herbal products.<sup>5,6</sup>

Plants and herbal medicines are frequently perceived to be safe and harmless; however, this is a widespread misconception. Several plants contain bioactive compounds that can be toxic to humans, either on their own or when consumed alongside prescription medications. This misperception of safety has contributed to reports indicating that approximately 15%–20% of individuals taking prescription drugs also use herbal supplements,<sup>7</sup> a practice that poses serious health risks. Herbal preparations are often used in combination and prepared using diverse methods, increasing the potential for contamination, adulteration, or presence of toxic compounds introduced during processing.<sup>8</sup> Toxicity stems from contamination, adulteration, and intrinsic properties of the plants themselves. These risks underscore the significance of rigorous toxicological and safety evaluations to ensure safe use. This review examined the toxicology of globally recognized herbal medicines, outlining their known toxic effects, associated clinical signs and symptoms, available treatments, and health outcomes.

## **Materials and Methods**

The literature was searched using different published resources and databases, PubMed, and ScienceDirect. The search terms included “herbal medicine,” “herbal remedies,” “traditional medicine systems,” “herbal toxicity,” “herbal toxicity mechanism of action/toxicity,” among others. The search was limited to the English language, and there were no restrictions on the date of publication.

## **Global Overview of Herbal Remedies**

### *Modern herbal formulations*

Technological advances have transformed the use of herbal remedies, which traditionally involve preparing decoctions from different plant parts, such as seeds, leaves, stems, bark, roots, or flowers, into standardized, scientifically validated formulations, such as extracts, capsules, tablets, tinctures, and nano-formulations.<sup>9</sup> These innovations have significantly improved the stability, bioavailability, efficacy, and safety profiles of herbal medicines, thereby facilitating their integration into modern health care systems and pharmaceutical development pipelines.<sup>9-11</sup>

Unlike traditional decoctions, modern herbal formulations are characterized by standardized concentrations of the active constituents, reproducible pharmacological activity, and rigorous quality control processes. Advanced extraction techniques, such as supercritical fluid extraction, microwave-assisted extraction, and ultrasonic extraction, enable the selective isolation of bioactive compounds, reduce variability, and improve consistency between batches. Furthermore, the development of novel drug delivery systems, including liposomes, phytosomes, nanoparticles, and transdermal patches, has enhanced the targeted delivery, solubility, and absorption of phytochemicals.

In addition, modern formulations have been subjected to preclinical and clinical evaluations to establish their safety, efficacy, and mechanisms of action. Regulatory agencies such as the European Medicines Agency and US Food and Drug Administration (FDA) have introduced frameworks for the approval of botanical drugs, further legitimizing herbal products within conventional therapeutic paradigms.

These advancements bridged traditional knowledge with modern science and addressed concerns regarding dosage accuracy, shelf life, contamination, and potential herb–drug interactions. Consequently, modern herbal formulations offer safer and more effective alternatives to traditional preparations, promoting greater consumer confidence and expanding their therapeutic applications in both preventive and curative health care.

#### *Prevalence of Herbal Medicine Use*

The use of herbal remedies is significantly higher among individuals with chronic illnesses compared to those without.<sup>12</sup> A US-based study investigating the prevalence of herbal medicine use among adults reported this association, and similar findings were observed in Ethiopia, where a high prevalence of use was also documented among chronically ill patients.<sup>13</sup> The Ethiopian study further revealed that women and individuals living in rural areas were particularly likely to depend on herbal remedies. The consistency of these findings across the 2 countries on different continents suggests a broader global trend in reliance on herbal medicines among people with chronic diseases. This pattern reflected the influence of cultural beliefs, accessibility, affordability, and perceived efficacy on health-seeking behaviors. These insights highlight the need to integrate traditional medicines into mainstream health care systems, particularly in resource-limited settings, to support the safe, effective, and informed use of herbal products.

In South Africa, multiple studies have documented the widespread use of herbal remedies among people living with HIV/AIDS.<sup>14-16</sup> Although these studies consistently reported the use of herbal treatments alongside antiretroviral therapy (ART), the proportion of concurrent users was relatively modest. Several individuals reported that they had used herbal remedies before initiating ART.<sup>15,16</sup> Similar patterns have been observed among patients with cancer, where herbal products are often employed to alleviate symptoms, enhance quality of life, or as part of efforts to treat the disease.<sup>17</sup> Nonetheless, concerns remain regarding the safety, efficacy, and potential interactions of these remedies with conventional medicines, particularly in the context of limited regulatory oversight.<sup>17</sup>

Several factors influence the decision to use herbal remedies, including cultural and traditional beliefs, dissatisfaction with conventional treatments, and a preference for more holistic or natural approaches to health. Furthermore, the affordability and accessibility of herbal products play significant roles in health care system worldwide. In several cases, individuals depend on recommendations from family members, community leaders, or traditional healers, especially in settings wherein trust in traditional knowledge systems remains strong. The widespread perception that natural products are safer or cause fewer side effects than pharmaceuticals further contributes to their use.<sup>18</sup> However, without proper regulation and oversight, the use of herbal remedies carries the risk of adverse effects or harmful drug interactions. These findings highlight the need for improved public health education and integration of traditional medicine into national health care frameworks to ensure the safe, effective, and responsible use of herbal therapies.

### **Common Toxic Herbal Remedies and Their Effects**

Herbal remedies are widely regarded as effective, a perception supported by their long history of use and the scientific validation and commercialization of certain preparations. However, as Paracelsus, the “father of toxicology,” famously stated, “All things are poison, and none are without poison; only the dose determines that a thing is not a poison.” This principle underscores that toxicity depends not only on the nature of a substance but also on the quantity consumed. The same applies to herbal medicines, which, when prepared as traditional decoctions, may deliver inconsistent doses of active compounds owing to variations in preparation methods, plant parts used, or concentrations of bioactive constituents. Such variability increases the risk of toxicity or diminishes therapeutic efficacy, particularly when remedies are administered at high doses or are used frequently.<sup>19</sup>

The use of herbal remedies has grown substantially in recent years, accompanied by the continued introduction of new products and formulations in the market. However, the absence of stringent regulatory oversight has raised growing concerns regarding their safety and potential public health risks.<sup>18</sup> Table 1 outlines the selection of plants that were later reported to exhibit toxic effects, while being widely used for medicinal purposes. Table 2 highlights 7 of the most commonly used traditional herbs that are known to possess inherent toxicities.

Several inherently toxic plants and herbs (Table 2) have been banned in multiple countries owing to safety concerns. In addition, reports of herbal-induced liver injury have increased over the last decade, with >12,000 publications documenting such cases between 2004 and 2020.<sup>20</sup>

### **Hepatotoxic Herbal Supplements and Abnormal Liver Function Tests**

Several herbal supplements are associated with hepatotoxicity, including commonly used products such as kava, comfrey, germander, chaparral, and green tea extracts. In several cases, abnormal liver function tests in otherwise healthy individuals are the first indication of herb-induced liver injury. Among these, kava, a herbal supplement traditionally used for its sedative and anxiolytic properties, is the most frequently cited. By 2003, 11 cases of hepatic failure were linked to kava use, of which 7 required liver transplantation and 4 resulted in death. Consequently, kava was banned in the European Union and Canada in January 2003, and the US FDA issued warnings regarding its safety. By 2009, >100 cases of kava-associated hepatotoxicity were reported.<sup>21</sup> Alcohol consumption is known to exacerbate kava-induced liver injury.

Kava contains 6 major kavalactones: methysticin, 7,8-dihydromethysticin, kavain, 7,8-dihydrokavain, yangonin, and desmethoxyyangonin, which together account for approximately 96% of its total kavalactone content. Commercial preparations are typically ethanol- or

acetone-based extracts, whereas traditional preparations in the South Pacific involve aqueous extractions.<sup>22</sup> Hepatotoxicity has been previously reported to be primarily associated with commercial solvent-based extracts, with traditional aqueous preparations considered safer. However, case studies and WHO reviews have demonstrated that aqueous kava extracts used in regions such as New Caledonia, Australia, the United States, and Germany may cause hepatotoxicity.<sup>23</sup>

Contamination with toxic alkaloids further increased this risk. Pipermethysticin, found in kava leaves and stems, may enter preparations through poor quality control, whereas flavokavains, alkaloids present in kava roots, have also been implicated in toxicity. Hepatocellular injury occurred via mitogen-activated protein kinase signaling, leading to oxidative stress and apoptosis. The chemical composition of kava products, and, thus, their potential toxicity, varies according to factors such as plant age, plant parts used, cultivation conditions, and geographic origin.<sup>24</sup>

Hepatotoxicity due to kava consumption is characterized by elevated serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase. In one documented case, a 50-year-old man who exceeded the recommended dose of 3 kava capsules daily for 2 months exhibited AST and ALT activities 60–70 times higher than the normal reference ranges. All hepatitis serology tests were negative, and kava consumption was identified as the cause of liver injury. The severity of the hepatotoxicity ultimately necessitated a liver transplant.<sup>25</sup>

Comfrey (*Symphytum officinale*), a perennial plant traditionally used for wound healing, bone repair, and the treatment of conditions such as arthritis, gout, and psoriasis, lacks scientific

evidence to support its use. Comfrey contains pyrrolizidine alkaloids that are potent hepatotoxins. Russian comfrey is more toxic than its European and Asian counterparts owing to its higher alkaloid content. Yeong et al described a case of a 23-year-old man who developed severe veno-occlusive disease and hypertension, ultimately dying from liver failure. Histological examination, including light microscopy and hepatic angiography, revealed occlusion of the sublobular veins and small venous radicles, accompanied by widespread hemorrhagic necrosis of hepatocytes, illustrating extensive liver damage linked to comfrey consumption. The patient, a vegetarian, had been using comfrey leaves as a dietary supplement.<sup>26</sup>

Germander (*Teucrium chamaedrys*) is an aromatic plant belonging to the mint family (Lamiaceae). The flowers have traditionally been used in folk medicine to treat dyspepsia, diabetes, and gout. However, chronic germander consumption has been associated with hepatotoxicity. Toxic effects typically appear within 9 weeks of use and are characterized by jaundice and elevated activities of liver enzymes, particularly ALT and AST. Recovery after discontinuation of the herb may occur between 6 weeks and 6 months. The mechanism of toxicity is believed to involve the metabolism of diterpenoid compounds into more potent toxic intermediates.<sup>27</sup>

A recent case report described a 45-year-old hypertensive woman who consumed 3 cups of boiled *Teucreum polium* (Felt's germander) in an attempt to induce abortion and was subsequently hospitalized. She presented with abdominal pain, weakness, lethargy, nausea, fever, chills, anorexia, and hematuria. Laboratory tests revealed severe hemolysis (lactate dehydrogenase, 3903 U/L) and a rapid drop in hemoglobin to 4.7 mg/dL within 12 hours. Additional findings included marked increases in the white blood cell count, reticulocyte count,

blood urea nitrogen, and creatinine levels. A peripheral blood smear demonstrated +3 schistocytes and acanthocytes. Viral markers and direct and indirect Coombs tests were negative. The patient was diagnosed with acute intravascular hemolysis accompanied by renal failure. With supportive treatment, including blood transfusions and intravenous hydration, her liver and kidney functions gradually improved, and she was ultimately discharged.<sup>28</sup>

Chaparral (*Larrea tridentata*), a plant native to the Southwestern United States and Northern Mexico, has traditionally been used as an herbal remedy for different ailments, ranging from cold sores to muscle pain. However, its use has been linked to severe hepatotoxicity, as evidenced by multiple reports of chaperone-associated hepatitis. Sheikh et al reviewed 18 cases of suspected central toxicity reported by the FDA and confirmed 13 cases of herb-induced liver injury. Clinical manifestations, typically jaundice with marked elevations in liver enzymes, appear between 3 and 52 weeks after chaparral ingestion and resolve within 1–17 weeks after discontinuation in most cases. Toxic or drug-induced cholestatic hepatitis is the predominant cause of liver injury. Among the reported cases, 4 progressed to cirrhosis, whereas 2 experienced acute fulminant liver failure necessitating liver transplantation.<sup>29</sup>

Pennyroyal (*Mentha pulegium*) is a mint family plant whose leaves emit a spearmint-like aroma when crushed. This fragrance is used in bath products and aromatherapies. Traditionally, pennyroyal has been consumed in small amounts as tea because of its abortifacient and emmenagogue properties. Plants and their essential oils contain several bioactive compounds, of which pulegone is the primary constituent. Pulegone is metabolized into the more toxic compound menthofuran in the liver and can deplete hepatic glutathione stores in a manner similar to an acetaminophen overdose.

Anderson et al. reported four cases of pennyroyal ingestion, one of which resulted in death. In the fatal case, postmortem serum analysis revealed pulegone and menthofuran concentrations of 18 ng/mL and 1 ng/mL, respectively. Notably, N-acetylcysteine, commonly used as an antidote for acetaminophen poisoning, was successfully employed to treat one of the surviving patients, while the two other patients, who ingested minimal amounts, did not require this intervention. The authors also reviewed 18 additional cases of pennyroyal toxicity, concluding that ingestion of as little as 10 mL of pennyroyal oil can cause severe poisoning.<sup>30</sup> Gordon and Khojasteh further noted that the majority of reported cases of pennyroyal toxicity and fatalities occurred in women who used the herb for its abortifacient effects.<sup>31</sup>

Green tea (*Camellia sinensis*) contains bioactive polyphenolic compounds, known as catechins, including epicatechin, epigallocatechin, gallocatechin, epicatechin gallate, and epigallocatechin-3-gallate (EGCG), which are potent antioxidants. Although moderate consumption of green tea (2–3 cups per day) is generally considered safe and beneficial, higher concentrations of EGCG, the primary active compound, can be hepatotoxic at higher concentrations. Products such as weight-loss supplements (eg, Slim Quick) contain concentrated green tea extracts, and regular consumption of these high-dose preparations is associated with liver toxicity.<sup>32</sup>

Numerous herbs have been associated with liver injury. For instance, skullcap (*Scutellaria lateriflora*) is traditionally used as a sedative and calming agent and is recommended for conditions such as nervous tension, epilepsy, and hysteria. Several reports of hepatotoxicity have involved skullcap taken in combination with other herbs, including valerian and *Ginkgo biloba*. Black cohosh (*Cimicifuga racemosa*) has been implicated in liver toxicity.<sup>33</sup>

Gotu kola (*Centella asiatica*, Sanskrit: Mandukaparni), a staple in Indian Ayurvedic medicine for managing hypertension and promoting wound healing, contains pentacyclic triterpenic saponosides, such as asiaticoside and madecassoside, which may contribute to hepatotoxic effects. In one study, 3 women aged 61, 52, and 49 years presented with markedly elevated liver enzyme activities: ALT values of 1193, 1694, and 324 U/L; ALP values of 503, 472, and 484 U/L; and bilirubin levels of 4.23, 19.89, and 3.9 mg/dL, respectively. All patients showed improvement after the discontinuation of herbal medication.<sup>34</sup>

### **Application of Digoxin Immunoassays to Detect Herbal Toxicity**

Chan Su is a traditional Chinese medicine derived from dried white secretions of the auricular and skin glands of the Chinese toad (*Bufo melanostictus* or *B. gargarzinas*). It is a key ingredient in other Chinese formulations, such as Liu-Shen-Wan and Kyushin, which are used to promote cardiac health. The cardiotoxic effects of Chan Su are primarily attributed to bufadienolides such as bufalin, cinobufagin, and resibufogenin. Bufalin is known to increase vasoconstriction, vascular resistance, and blood pressure, possibly by inhibiting the Na<sup>+</sup>/K<sup>+</sup>-ATPase activity. High doses of Chan Su can induce cardiac arrhythmias, seizures, and coma, with fatalities reported. For instance, a woman died after consuming Chinese herbal tea containing Chan Su.<sup>35</sup>

Ingestion of Chan Su can also result in digoxin-like immunoreactivity in serum due to structural similarities between bufalin, cinobufagin, and digoxin. Panesar reported a fatal case in which a woman who consumed Chan Su had an apparent digoxin level of 4.9 ng/mL.<sup>36</sup> Consequently, detection of digoxin in a patient not taking the drug may serve as an indirect marker of Chan Su poisoning.

Oleanders (*Nerium oleander* and *Thevetia peruviana*) are evergreen ornamental shrubs with pink, white, or bright yellow flowers that grow in the tropical and subtropical regions worldwide. All parts of these plants were toxic. Yellow oleander (*T. peruviana*) contains at least 8 toxic cardiac glycosides, including thevetin A, thevetin B, thevetoxin, neriifolin, peruvoside, and ruvoside, whereas the cardiotoxicity of pink or white oleander (*N. oleander*) is primarily attributed to oleandrin. Notably, oleandrin is resistant to inactivation by boiling and drying. Deliberate oleander ingestion is a common method of suicide in Sri Lanka, with an estimated fatality rate of approximately 10%. Both plants have been used as herbal preparations to promote cardiac health. The measurement of apparent digoxin concentrations using a digoxin immunoassay in patients not taking digoxin can aid in the diagnosis of oleander poisoning.<sup>37</sup>

### **Issues of Heavy Metal Toxicity in Chinese Herbal and Indian Ayurvedic Medicines**

Heavy metals and pesticides are common contaminants in Chinese herbal medicines. Harris et al analyzed 334 samples of Chinese herbal products and found that every sample contained at least one heavy metal (lead (Pb), arsenic (As) chromium (Cr), mercury (Hg), or cadmium (Cd), whereas 115 samples (34%) had detectable levels of all 5 metals. In addition, 42 pesticides were detected in 108 samples (36.7%).<sup>38</sup>

Zuo et al. measured the concentrations of lead, cadmium, arsenic, mercury, and copper in 2,245 batches of Chinese herbal medicines using inductively coupled plasma-mass spectrometry (ICP-MS), reporting mean concentrations of 1.566, 0.299, 0.391, 0.074, and 8.386 mg/kg, respectively.<sup>39</sup> Similarly, Yang et al. evaluated 10,245 samples across 279 types of Chinese herbal medicines for toxic heavy metals using a validated ICP-MS method. Their analysis identified high-risk contamination for specific herbs: lead in *Cibotii* rhizome, *Selaginellae*

*herba*, *Morindae officinalis radix*, *Asprellae ilicis radix*, and *Toxicodendri resina*; arsenic in *Eckloniae/Laminariae thallus*, *Spirodela herba*, and *Naturalis indigo*; cadmium in *Tetrapanacis medulla*, *Centipeda herba*, *Cyathulae radix*, *Linderae radix*, *Meretricis/Cyclinae concha*, and *Tabanus*; and mercury in *Toxicodendri resina*.<sup>40</sup>

Heavy metal toxicity caused by herbal products has been previously documented. For instance, a 30-year-old Indian sailor developed microcytic anemia (Hb 9.9 g/dL), persistent abdominal pain, vomiting, dark stools, hyperchromic urine, latent jaundice, and asthenia after consuming Ayurvedic medicine. Blood analysis confirmed severe lead intoxication (blood lead level of 102 mcg/dL), and the patient was treated with chelation therapy. Subsequent analysis of the Ayurvedic preparations revealed high levels of lead.<sup>41</sup> Arsenic poisoning following consumption of Indian Ayurvedic medicines has also been reported.<sup>42</sup>

.

### **Herbal Supplements Contaminated with Western Drugs**

Another significant source of herbal medicine toxicity is adulteration by undisclosed Western pharmaceuticals. These synthetic drugs are not listed on product labels, creating serious risks of toxicity. For instance, in one study that analyzed 2069 samples of traditional Chinese medicines collected from 8 hospitals in Taiwan, undeclared pharmaceuticals were detected in 618 samples (23.7%). The most common are caffeine, acetaminophen, indomethacin, hydrochlorothiazide, and prednisolone.<sup>43</sup> Several of these products are marketed for pain relief, inflammation, or arthritis management, which can be achieved by the adulterants themselves. Of particular concern is the presence of corticosteroids, such as prednisolone, which carry significant risks when used without medical supervision.

Sibutramine, an oral anorexiant, is another commonly reported adulterant in herbal slimming products and dietary supplements.<sup>44</sup> A case report described a 33-year-old woman with an eight-year history of epilepsy treated with valproate, carbamazepine, and phenobarbital, but never with phenytoin. Following the use of three proprietary Chinese medicines in addition to her prescribed therapy, she presented with toxic phenytoin levels (48.5 mg/mL). Laboratory analyses revealed that one preparation (Jue Dian Shen Ying Wan, orange capsule) contained 41 mg of phenytoin, despite the manufacturer's claim that the capsules contained only Chinese herbal ingredients for epilepsy management.<sup>45</sup>

Similarly, Savaliya et al reported adulteration of Indian Ayurvedic medicine. Of the 58 products analyzed, 10 contained undeclared steroidal or nonsteroidal anti-inflammatory drugs. Dexamethasone and diclofenac were the most frequently detected drugs, whereas piroxicam was found in one preparation and dexamethasone in the other.<sup>46</sup>

## **Clinical Management of Herbal Toxicity**

### *General Management Principles*

In most countries, herbal remedies are usually obtained over the counter, rather than by prescription or purchased from informal markets. Some patients may require a prescription; however, this depends on the regulatory framework and specific herbal product. For the latter, pharmacists play a vital gatekeeping and advisory role in ensuring safe use, preventing harmful interactions, and promoting evidence-based decision making in health care.

Effective management of potential herbal toxicity begins with a comprehensive clinical assessment. This process should begin with a detailed history-taking, which involves gathering information about the specific herbal products or products consumed. Clinicians should attempt

to obtain the botanical name, if known, and the brand or source of the product, method of preparation, dosage, frequency, and duration of use, and whether the herbal remedy is used in combination with other medications or substances.

A thorough physical examination is essential and should focus on identifying any signs of systemic toxicity. Particular attention should be paid to the potential involvement of hepatic, renal, cardiovascular, and neurological systems, which are often affected by herbal toxicity.

Baseline investigations should be conducted to support clinical assessments. These may include tests such as liver and renal function panels, serum electrolytes, complete blood count, coagulation profiles, urinalysis, and electrocardiography. The choice of test depends on the clinical presentation and type of suspected toxicity.

Clinicians should maintain a high index of suspicion when evaluating patients with unexplained symptoms, particularly in those with a history of herbal product use. Prompt identification of the causative agent and immediate discontinuation are crucial steps to prevent further harm and improve clinical outcomes.

#### *Symptomatic and Supportive Treatment*

In most cases of herbal toxicity, management is primarily supportive and guided by the patient's presenting symptoms, because specific antidotes for several herbal toxins are unavailable. The symptomatic care focuses on minimizing further harm, stabilizing the patient, and supporting the affected organ systems.

Gastrointestinal decontamination is one of the initial steps in some cases. If a toxic herb is ingested, the patient presents within the first hour, is clinically stable, and the substance is known to benefit from decontamination, activated charcoal may reduce systemic absorption.

Hydration and electrolyte management are critical care components. Intravenous fluids should be administered to maintain adequate perfusion, and electrolyte imbalances must be corrected, especially in patients with vomiting, diarrhea, or signs of renal involvement.

Specific support strategies must be implemented in cases of organ dysfunction. In cases of hepatotoxicity, liver enzyme and bilirubin levels should be closely monitored. Referral to a hepatologist or evaluation for liver transplantation may be necessary if the liver injury is severe. Ensuring adequate hydration is essential to prevent nephrotoxicity, and renal function should be regularly assessed. Dialysis was indicated if renal failure developed.

Cardiotoxicity requires continuous electrocardiography monitoring, appropriate management of arrhythmias, and hemodynamic support where necessary. In patients exhibiting neurotoxicity, seizures should be controlled using benzodiazepines, and clinicians should assess for signs of altered mental status or encephalopathy.

Inhaled corticosteroids may be required for critically ill patients, particularly those with respiratory compromise or unstable blood pressure. These include mechanical ventilation and vasopressor therapy to maintain adequate oxygenation and perfusion. Overall, the management approach should be individualized and responsive to specific clinical manifestations and toxicity severity.

### *Use of Specific Antidotes*

Although specific antidotes for herbal toxins are generally limited, they can be employed in situations where the causative agent has been identified. When available and appropriate, antidotes play crucial roles in mitigating toxicity and improving patient outcomes.

N-Acetylcysteine is an antidote commonly used in cases of liver injury, particularly when the clinical presentation resembles that of paracetamol toxicity. It may also be beneficial in cases of hepatotoxicity resulting from herbal products, such as *T. chamaedrys* (Germander) or *Polygonum multiflorum* (Chinese knotweed). Atropine is indicated in situations involving anticholinergic poisoning or bradyarrhythmias caused by herbs containing alkaloids, such as *Atropa belladonna* (deadly nightshade). Its administration counteracted the muscarinic effects of these toxins. In cases of cardiac glycoside toxicity, particularly from herbal sources such as *Digitalis purpurea* (foxglove) or *T. peruviana* (yellow oleander), digoxin-specific antibody fragments (Digibind) may be considered. These antibodies can neutralize toxic effects and support cardiac stabilization. Physostigmine may be used to reverse central anticholinergic toxicity; however, considering its potential for serious adverse effects, it should be administered with extreme caution, ideally under the guidance of a toxicologist.

Despite the presence of specific antidotes, no targeted therapy is available in several instances. In such cases, management must depend entirely on supportive care and vigilant monitoring tailored to the patient's clinical status and affected systems.

### *Role of Toxicology Services and Poison Control Centres*

Consultation with a poison control center or clinical toxicologist can provide real-time evidence-based guidance on risk assessment, the need for hospital admission, decontamination

strategies, and antidotal therapy. These services are particularly helpful when dealing with unfamiliar herbs or when plant misidentification is suspected.

#### *Patient Education and Prevention*

Preventive strategies are essential to reduce the risk of recurrent herbal toxicity and promote the safe use of herbal products. Therefore, patient education is an important measure. Clinicians are responsible for informing patients about the potential risks associated with the use of herbal supplements, particularly when taken with prescription medications. Several herbal products interact with conventional drugs, causing adverse effects or reduced therapeutic efficacy.

Creating an open and nonjudgmental environment wherein patients feel comfortable disclosing all forms of alternative therapies is essential. Encouraging transparency during medical consultations enables clinicians to identify potential risks early and provide appropriate guidance.

In addition, patients should be made aware of the lack of standardization and regulations for the production and marketing of herbal products. Unlike pharmaceutical drugs, herbal remedies are often not subjected to rigorous quality control, causing variability in their composition, contamination, or mislabeling. Clinicians should advise patients to use only well-researched and reputable formulations, ideally those that have undergone safety evaluations or are supported by scientific evidence.

Health care providers safeguard patients from future episodes of herbal toxicity by integrating these preventive approaches into routine clinical practice and promoting the use of complementary therapies.

**Conclusion**

Although herbal remedies offer valuable therapeutic benefits and are widely used worldwide, their potential toxicity and harmful interactions cannot be overlooked. Advances in modern formulations and increased regulatory oversight have improved safety; however, gaps remain, particularly in public awareness and standardized regulations. Comprehensive clinical management, patient education, and integration of traditional medicine into mainstream health care are essential to ensure the safe, effective, and responsible use of herbal products. Ongoing research and collaboration between traditional and modern medical systems are the keys to maximizing the benefits of herbal therapies while minimizing the associated risks.

**Table 1:** Plants commonly used as traditional remedies later found to have toxic effects

Latin name	Family	Common/ vernacular name	Traditional use	Adverse effects	Clinical evidence	Possible mechanisms of toxicity
<i>Teucrium chamaedrys</i> , <i>T. polium</i> , <i>T. capitatum</i> , <i>T. viscidum</i>	Lamiaceae	Germander	Dyspepsia, anorexia, nasal catarrh, chronic bronchitis, gout, rheumatoid arthritis, fever, uterine infections, wound healing, weight loss. <sup>47</sup>	Increased serum levels of liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), $\gamma$ glutamyl-transpeptidase ( $\gamma$ -GT), steatosis, hepatomegaly. <sup>47</sup>  Several cases of liver disease (hepatitis), death. <sup>48</sup>	35 cases of hepatotoxicity, 2 of which were fatal and 4 causing chronic hepatitis. <sup>48</sup>  Capsules containing germander, either alone or combined, are marketed as weight-control supplements and have been associated with hepatotoxicity as reported in about thirty cases from France. <sup>49</sup>  Toxicological studies showed that one of the major furano neo-clerodane diterpenoids, teucriin A, was implicated in the hepatotoxicity of germander. <sup>50</sup>	Activation of cytochrome P450 (mainly CYP3A) into reactive metabolites. The reactive electrophilic metabolites stimulate apoptosis by decreasing thiols (glutathione conjugate formation) which increases intracellular calcium. <sup>51</sup>  Metabolic activation of teucriin A in rats results in extensive damage of numerous hepatic proteins (involved in lipid, amino acid and drug metabolism, mitochondrial and peroxisomal enzymes) by covalent modification. <sup>52</sup>  The formation of reactive metabolites may also lead to immune reactions. <sup>53</sup> Therefore, it is likely that germander-induced hepatotoxicity may be due to direct and secondary immune reactions.

<i>Hypericum perforatum</i>	Hypericaceae	St John's wort	Anxiety and depressive and sleep disorders. <sup>54</sup>	Dry mouth, dizziness, constipation, other GI symptoms, and confusion. <sup>55</sup>	<p>Long-term St John's wort administration resulted in a significant and selective induction of CYP3A activity in the intestinal wall.<sup>54, 56</sup></p> <p>Interactions with prescribed medicines including warfarin, phenprocoumon, cyclosporin, HIV protease inhibitors, theophylline, digoxin and oral contraceptives result in a decrease in concentration and therefore decreased efficacy.<sup>57</sup></p>	<p>Induction of CYP3A4, CYP2C9 and CYP1A2 activity and the transport protein P-glycoprotein.<sup>54, 56</sup></p> <p>St John's wort binds to the pregnane X receptor responsible for the expression of CYP3A4.<sup>57</sup></p> <p>Monoamine oxidase-inhibiting effects may cause increased levels of serotonin, dopamine and norepinephrine.<sup>54</sup></p>
<i>Ginkgo biloba</i>	Ginkgoaceae	Ginkgo	Improvement of cognitive functioning, <sup>56</sup> memory loss, dementia, poor concentration, glaucoma, cerebral insufficiency and peripheral circulatory disturbances	<p>Precipitation of seizure.<sup>58</sup></p> <p>Spontaneous bleeding and may interact with anticoagulants and antiplatelet agents.<sup>54</sup></p>	<p>Two patients with controlled epilepsy presented with recurrent seizures within 2 weeks of commencing extract of <i>Ginkgo biloba</i><sup>58</sup></p> <p>A fatal seizure in a 55-year-old male due to potential herb-drug interactions with <i>Ginkgo biloba</i><sup>59</sup></p>	<p>Induction of CYP2C19 is responsible for the metabolism of many anticonvulsant medications resulting in sub-therapeutic concentrations of the medication thereby precipitating seizures and possibly causing death.<sup>59,60</sup></p> <p>Ginkgolides, biologically active constituents of <i>Ginkgo biloba</i> are potent inhibitors of platelet aggregating factors, resulting in the increased vasodilation and peripheral blood flow rate leading to serious adverse effects such as prolonged bleeding times and spontaneous subdural hematomas.<sup>61,62</sup></p>

<i>Thevetia peruviana</i>	Apocynaceae	Yellow oleander	Antibacterial, antifungal, <sup>63</sup> abortifacient, diuretic, cardiotoxic, emetic and purgative. <sup>63</sup>	<p>Gastrointestinal and cardiac symptoms, local irritation of mucous membranes, nausea, vomiting, severe diarrhoea, abdominal pain, dilated pupils and convulsions.<sup>63</sup></p> <p>Cardiovascular manifestations range from sinus brady-cardia with sino-atrial block to first and second-degree heart block, junctional rhythms, A-V block, atrial and ventricular ectopic beats, ventricular fibrillation.<sup>63,64</sup></p>	168 cases of human poisoning in Sri Lanka. <sup>64</sup>	<p>Cardiac glycosides exert a digoxin-like effect by inhibiting the sodium-potassium adenosine- triphosphatase (ATP) enzyme systems. The increased intracellular sodium concentration and the increased serum potassium concentration produce a negative chronotropic and positive inotropic effect.<sup>65</sup></p> <p>The resulting toxic syndrome resembles digitalis poisoning with marked hyperkalemia, conduction abnormalities and ventricular arrhythmias.<sup>66</sup></p>
---------------------------	-------------	-----------------	--	---	--	--

**Table 2:** Inherently toxic herbs, their common use, mechanism of injury including the clinical presentation of poisoning with these herbs and treatment

<b>Herb</b>	<b>Common Use</b>	<b>Inherent Toxicity</b>	<b>Mechanism of Toxicity/Injury</b>	<b>Signs &amp; Symptoms</b>	<b>Treatment</b>
<b>Kava</b> ( <i>Piper methysticum</i> )	Anxiety, sleep disorders. <sup>67, 68</sup>	Hepatotoxicity. <sup>69, 70</sup>	Inhibits some cytochrome P450 isoenzymes, and CYP 2E1, <sup>69</sup> herb-drug interaction, <sup>71</sup> glutathione depletion. <sup>72</sup>	Fatigue, liver failure, nausea, vomiting, <sup>71</sup> elevated liver enzymes. <sup>73</sup>	Liver transplant and discontinue use. <sup>74</sup>
<b>Ephedra</b> ( <i>Ma Huang</i> )	Weight loss, performance enhancement, mental acuity, allergies, asthma etc. <sup>69,75</sup>	Cardiovascular toxicity and idiosyncratic liver injury, <sup>69</sup> elevated blood pressure. <sup>76</sup>	Sympathomimetic stimulation via ephedrine alkaloids. <sup>77</sup>	Hypertension and palpitations, <sup>76</sup> myocardial infarction. <sup>77</sup>	
<b>Aristolochia spp.</b>	Seizures prevention, elevates libido, boost the immune system, and start menstruation. <sup>78</sup>	Nephropathy, <sup>79,80</sup> and carcinogenicity. <sup>79,81</sup>	Plants contains aristolochic acid which leads to the formation of DNA adducts. <sup>82,83</sup>	Renal failure, gastrointestinal abnormality, anemia, hypertension, <sup>84</sup> urothelial cancers. <sup>85</sup>	Discontinue use, dialysis, kidney transplant in severe cases. <sup>85</sup>
<b>Comfrey</b> ( <i>Symphytum spp.</i> )	Wound healing, alleviates joint pain and inflammation. <sup>86-88</sup>	Hepatotoxicity, <sup>69</sup> carcinogenicity. <sup>89</sup>	Pyrrrolizidine alkaloids damage the hepatic endothelial cells and can cause sinusoidal obstruction. <sup>69</sup>	Right upper quadrant pain, nausea, fluid retention) and jaundice. <sup>69</sup>	Avoid continued use, treatment should target associated clinical problems. <sup>90</sup>
<b>Aconite</b> ( <i>Aconitum spp.</i> )	Pain, rheumatism, and lethargy. <sup>91</sup>	Toxicosis, cardiotoxic and neurotoxic effects, <sup>67</sup> ventricular tachyarrhythmia and heart arrest. <sup>92</sup>	Interference with cellular metabolic pathways, interference with microRNA expression, modulating calcium channels, sodium potassium ATPase pumps, and decreasing acetylcholine release. <sup>93</sup>	Ventricular tachycardia, mild gastrointestinal effects, from seizures and fatal dysrhythmias. <sup>93</sup>	Gastric decontamination with activated charcoal if ingested and supportive care. <sup>93</sup>

<b>Herb</b>	<b>Common Use</b>	<b>Inherent Toxicity</b>	<b>Mechanism of Toxicity/Injury</b>	<b>Signs &amp; Symptoms</b>	<b>Treatment</b>
<b>Pennyroyal</b> ( <i>Mentha pulegium</i> )	Purifying blood, headaches, hoarseness, nausea, soothe bruises, clear spots, <sup>94</sup> induce abortion. <sup>95</sup>	Acute liver injury, cardiovascular collapse coupled with intravascular coagulation. <sup>69</sup>	Plant contains pulegone which is converted by the cytochrome P450 system (CYP 1A2 and 2E1) to other hepatotoxins (menthofuran) therefore inducing liver and multiorgan injury. <sup>69</sup>	Abdominal pain, nausea, vomiting, lethargy and agitation. <sup>95</sup>	Discontinue use
<b>Chaparral</b> ( <i>Larrea tridentata</i> )	Cancer, arthritis, tuberculosis, skin conditions and the cold. <sup>96,97</sup>	Hepatotoxicity. <sup>69, 97</sup>	Nordihydroguaiaretic acid (NDGA) affects intrahepatic pathways. <sup>69</sup>	Jaundice, fatigue, liver enzyme elevation. <sup>98</sup>	Discontinue, monitor liver function, supportive treatment

## References

1. World Health Organization. Global report on traditional and complementary medicine 2019. Geneva, Switzerland; 2019.
2. Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. *Fitoterapia*, 2010; 81(6): 462-471.
3. World Health Organization. Guidelines for the regulation of herbal medicines in the South-East Asia Region. 2004.
4. Chevallier A. Encyclopedia of herbal medicine: 550 herbs and remedies for common ailments. Third Edition. Penguin Random House, London, 2016.
5. Balkrishna A, Sharma N, Srivastava D, et al. Exploring the safety, efficacy, and bioactivity of herbal medicines: Bridging traditional wisdom and modern science in healthcare. *FIM*. 2024;3(1):35-49.
6. Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: Ahmad I, ed. *Modern phytomedicine: Turning medicinal plants into drugs*. 1<sup>st</sup> ed. KGaA, Weinheim, Wiley-VCH Verlag GmbH & Co; 2006:25-57.
7. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. *JAMA*. 1998; 280(18):1569-1575.
8. Benzie IF, Wachtel-Galor S. Herbal medicine: Biomolecular and clinical aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
9. Alam G, Mishra AK. Traditional and modern approaches for standardization of herbal drugs:A review. *Acta Biomedica Scientia*. e-ISSN. 2017; 2348: 2168.
10. Yunita O, Pradana RP, Sari NLP, et al. Development of online information card about Indonesian herbal medicine. 2022. <http://repository.ubaya.ac.id/id/eprint/43812>. Accessed 04 June 2025
11. Dalabehera M, Subudhi RN. Herbal formulations for targeted drug delivery systems. *Innovative Pharmaceutical Excipients: Natural Sources*. Springer Nature 2025;77-94.
12. Rashrash M, Schommer JC, Brown LM. Prevalence and predictors of herbal medicine use among adults in the United States. *J Patient Exp*. 2017;4(3):108-113.
13. Tassew WC, Assefa GW, Zeleke AM, et al. Prevalence and associated factors of herbal medicine use among patients living with chronic disease in Ethiopia: a systematic review and meta-analysis. *Metabolism Open*. 2024:100280.

14. Peltzer K, Preez NFD, Ramlagan S, et al. Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa. *BMC Public Health*. 2008; 8:1-14.
15. Hughes GD, Puoane TR, Clark BL, et al. Prevalence and predictors of traditional medicine utilization among persons living with AIDS (PLWA) on antiretroviral (ARV) and prophylaxis treatment in both rural and urban areas in South Africa. *Afr J Tradit Complement Altern Med*. 2012; 9(4):470-484.
16. Sibanda M, Manimbulu NM, Naidoo P. Concurrent use of Antiretroviral and African traditional medicines amongst people living with HIV/AIDS (PLWA) in the eThekweni Metropolitan area of KwaZulu Natal. *Afr Health Sci*. 2016;16(4): 1118-1130.
17. Al-Masri M, Darwish R, Safi Y, et al. Herbal and alternative medicine use: a cross sectional study to evaluate the prevalence and predictors of use in cancer patients. *Front. Pharmacol*. 2025;16:1535795.
18. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. *Front. Pharmacol*. 2014; 4: 177.
19. Chaudhari R, Bele S. Herbal vs. Synthetic: The Drug Comparison. *IJRPR*. 2024;5(11):3494-3507.
20. Patel-Rodrigues PA, Cundra L, Alhaqqan D, et al. Herbal- and dietary-supplement-induced liver injury: A review of the recent literature. *Livers*. 2024; 4(1):94-118.
21. Li XZ, Ramzan I. Role of ethanol in kava hepatotoxicity. *Phytother Res*. 2010; 24: 475-480.
22. Ketola RA, Vinamaki J, Rasanen I, Pelander A et al. Fatal kava lactone intoxication by suicidal intravenous injection. *Forensic Sci Int*. 2015; 249:e7-11.
23. Teschke R, Sarris J, Schwetzer I. Kava hepatotoxicity in traditional and modern use: The presumed pacific kava paradox hypothesis revisited. *Br J Clin Pharamcol*. 2012; 73:170-174.
24. Rowe A, Zhang LY, Ramzan I. Toxicokinetics of kava. *Adv Pharamcol Sci*. 2011; 1:326724.
25. Escher M, Desmeules J. Hepatitis associated with kava, a herbal remedy. *BMJ*. 2001;322 (7279): 139.
26. Yeong ML, Swinburn B, Kennedy M, Nicholson G Hepatic veno-occlusive disease associated with comfrey ingestion. *J Gastroenterol Hepatol*. 1990; 5: 211-214.

27. Seeff LB. Herbal hepatotoxicity. *Clin Liver Dis.* 2007; 11: 577-596.
28. Gholami L, Ahmadi SM, Pursusan S. Acute kidney failure and hemolysis secondary to high-dose *Teucreum polium* (Lamiaceae): Case report. *Clin Case Rep.* 2025;13(3):e70294.
29. Sheikh NM, Philen RM, Love LA. Chaparral associated hepatotoxicity. *Arch Intern Med.* 1997; 157(8): 913-919.
30. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolites levels in two cases and review of literature. *Ann Intern Med.* 1996; 124(8): 726-734.
31. Gordon P, Khojasteh SC. A decades-long investigation of acute metabolism-based hepatotoxicity by herbal constituents: A case study of pennyroyal oil. *Drug Metab Rev.* 2015; 47(1): 12-20.
32. de Boer YS, Sherker AH. Herbal and dietary supplement-induced liver injury. *Clin Liver Dis.* 2017; 21(1): 135-149.
33. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. *Med J Aust.* 2002; 177(8): 440-443.
34. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of *Centella asiatica*. *Rev Esp Enferm Dig.* 2005; 97(2): 115-124 [Article in Spanish].
35. Ko RJ, Greenwald MS, Loscutoff SM, et al. Lethal ingestion of Chinese tea containing Chan SU. *West J Med.* 1996; 164: 71-75.
36. Panesar NS. Bufalin and unidentified substances in traditional Chinese medicine cross react in commercial digoxin assay. *Clin Chem.* 1992; 38(10): 2155-2156.
37. Dasgupta A. Herbal supplements and therapeutic drug monitoring: Focus on digoxin immunoassays and interactions with St. John's Wort. *Ther Drug Monit.* 2008; 30(2):212-217.
38. Harris ES, Cao S, Littlefield BA, et al. Heavy metal and pesticides content in commonly prescribed individual raw Chinese herbal medicines. *Sci Total Environ.* 2011; 409(20): 4297-4305.
39. Zuo TT, Jin HY, Zhang L, et al. Innovative health risk assessment of heavy metals in Chinese herbal medicines based on extensive data. *Pharmacol Res.* 2020;159(9):104987.

40. Yang CM, Chien MY, Chao PC, et al. Investigation of toxic heavy metals content and estimation of potential health risks in Chinese herbal medicine. *J Hazard Mater.* 2021;412(6):125142
41. Ciocan C, Mansour I, Beneduce A, et al. Lead poisoning from Ayurvedic treatment: A further case. *Med Lav.* 2021;112(2):162-167.
42. Pinto B, Goyal P, Flora SJ, et al. Chronic arsenic poisoning following ayurvedic medication. *J Med Toxicol.* 2014 ;10(4):395-398.
43. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. *J Clin Pharmacol.* 1997; 37(4): 344-350.
44. Shapira B, Goldstein L, Reshef A, et al. A rare case of psychomotor disturbances linked to an adulterated dietary supplement containing sibutramine. *Clin Neuropharmacol.* 2016; 39(3): 154-156.
45. Lau KK, Lai CK, Chan AYW. Phenytoin poisoning after using Chinese proprietary medicines. *Hum Exp Toxicol.* 2000; 19(7): 385-386.
46. Savaliyaa AA, Prasad B, Rajjada DK, et al. Detection and characterization of synthetic steroidal and non-steroidal antiinflammatory drugs in Indian Ayurvedic/herbal products using LC-MS/TOF. *Drug Test Anal.* 2009; 1(8): 372-381.
47. Shilo S, Hirsch HJ. Iodine-induced hyperthyroidism in a patient with a normal thyroid gland. *Postgrad Med J.* 1986; 62(729): 661-662.
48. Müssig K, Thamer C, Bares R, et al. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. *J Gen Intern Med.* 2006; 21(6):C11-C14.
49. Michelot D, Siobud E, Doré JC, et al. Update on metal content profiles in mushrooms: Toxicological implications and tentative approach to the mechanisms of bioaccumulation. *Toxicol.* 1998;36(12): 1997-2012.
50. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. *J Gen Intern Med.* 2008;23(6): 854-859.
51. Choi JG, Eom SM, Kim J, et al. A comprehensive review of recent studies on herb-drug interaction: a focus on pharmacodynamic interaction. *J Altern Complement Med.* 2016; 22(4):262-279.

52. Druckova A, Mernaugh RL, Ham AJL, et al. Identification of the protein targets of the reactive metabolite of teucrin A in vivo in the rat. *Chem Res Toxicol.* 2007; 20(10):1393-1408.
53. Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb–drug interactions. *Front. Pharmacol.* 2012; 3(4): 69.
54. Gurley B.J. Pharmacokinetic herb-drug interactions (part 1): Origins, mechanisms, and the impact of botanical dietary supplements. *Planta Medica.* 2012;78(13): 1478-1489.
55. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): Drug interactions involving popular botanical dietary supplements and their clinical relevance. *Planta Medica.* 2012. 78(13):1490-1514.
56. Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement–drug interactions. *Am Fam Physician.* 2017. 96(2):101-107.
57. Aggarwal A, Ades PA, Interactions of herbal remedies with prescription cardiovascular medications. *Coronary Artery Disease.* 2001;12(7): p. 581-584.
58. Sood A, Sood R, Brinker FJ, et al. Potential for interactions between dietary supplements and prescription medications. *AM J Med.* 2008;121(3): 207-211.
59. Di YM, Li CG, Xue CC. et al. Clinical drugs that interact with St. John's wort and implication in drug development. *Curr Pharm Des.* 2008. 14(17): 1723-1742.
60. Newall CA, Anderson LA, Phillipson JD. Herbal medicines. A guide for health-care professionals. UK, London. The Pharmaceutical Press;1996.
61. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. *Ther. Drug Monit.* 2008;30(2): 212-217
62. Zhang J, Wider B, Shang H, et al. Quality of herbal medicines: challenges and solutions. *Complement Ther Med.* 2012; 20(1-2):100-106.
63. Parasuraman S. Toxicological screening. *J Pharmacol Pharmacother.* 2011;2(2): 74.
64. Fonseka MM, Seneviratne SL, De Silva CE, et al. Yellow oleander poisoning in Sri Lanka: Outcome in a secondary care hospital. *Hum. Exp. Toxicol.* 2002;21(6): 293-295.
65. Ellenhorn MJ, Barceloux DG. Medical toxicology: Diagnosis and treatment of human poisoning. New York, NY. Elsevier Science Publishing Co;1988.

66. Frohne D. A colour atlas of poisonous plants: a handbook for pharmacists, doctors, toxicologists, and biologists. Wolfe Pub, London; 1984.
67. Sabrina Felson, M. What Is Kava Kava? <https://www.webmd.com/vitamins-and-supplements/what-is-kava-kava>. Accessed 12 June 2025
68. Ali R, Tariq S, Kareem O, et al. Nutraceuticals for sleep disorders. *CCHTS*. 2021;24(10): 1583-1592.
69. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID: 31643176. <https://www.ncbi.nlm.nih.gov/books/NBK547852/>
70. Ernst E. A re-evaluation of kava (*Piper methysticum*). *BJCP*. 2007; 64(4): 415.
71. Fu PP, Xia Q, Guo L, et al. Toxicity of kava kava. *J. Environ. Sci. Health C*. 2008; 26(1):89-112.
72. Whitton PA, Lau A, Salisbury A, et al. Kava lactones and the kava-kava controversy. *Phytochemistry*. 2003; 64(3): 673-679.
73. Clouatre DL. Kava kava: examining new reports of toxicity. *Toxicol Lett*. 2004; 150(1):85-96.
74. Amorim MF, Diniz MF, Araújo M.S, et al. The controvertible role of kava (*Piper methysticum* G. Foster) an anxiolytic herb, on toxic hepatitis. *Rev Bras Farmacogn*. 2007;17(3):448-454.
75. Zheng Q, Mu X, Pan S, et al. *Ephedrae herba*: A comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology. *J Ethnopharmacol*. 2023; 307(5): 16153.
76. Harvard Health Publishing. The dangers of the herb ephedra. 2017. <https://www.health.harvard.edu/staying-healthy/the-dangers-of-the-herb-ephedra>. Accessed 13 June 2025
77. Powell T, Hsu FF, Turk J, et al. Ma-huang strikes again: ephedrine nephrolithiasis. *Am J Kidney Dis*. 1998; 32(1):153-159.
78. WebMD. Aristolochia: Uses, side effects, and more. 2024. <https://www.webmd.com/vitamins/ai/ingredientmono-583/aristolochia>. Accessed 13 June 2025
79. Politi M, Simonet N, Kube E, et al. Ethnomedical uses of Yawar Panga (*Aristolochia didyma*) in a therapeutic community dedicated to the treatment of drug addiction in the Peruvian Amazon. *NRFHH*. 2023;3(2): 248-258.

80. Heinrich M, Chan J, Wanke S, et al. Local uses of *Aristolochia* species and content of nephrotoxic aristolochic acid 1 and 2: A global assessment based on bibliographic sources. *J Ethnopharmacol.* 2009; 125(1):108-144.
81. Tomlinson T, Fernandes A, Grollman AP. *Aristolochia* herbs and iatrogenic disease: the case of Portland's powders. *Yale J. Biol. Med.* 2020; 93(2):355.
82. Han J, Xian Z, Zhang Y, et al. Systematic overview of aristolochic acids: Nephrotoxicity, carcinogenicity, and underlying mechanisms. *Front. Pharmacol.* 2019; 10(6): 648.
83. Zhang Q, Chen J, He H, et al. Hepatotoxic effects of aristolochic acid: Mechanisms and implications. *Acta Materia Medica.* 2024; 3(3):349-362.
84. Zhou Q, Jiang L, Su T, et al. Overview of aristolochic acid nephropathy: An update. *Kidney Res Clin Pract.* 2023; 42(5):579.
85. Grollman AP, Marcus DM, Global hazards of herbal remedies: Lessons from *Aristolochia*: The lesson from the health hazards of *Aristolochia* should lead to more research into the safety and efficacy of medicinal plants. *EMBO reports.* 2016; 17(5):619-625.
86. HealthLine. What Is Comfrey? <https://www.healthline.com/health/what-is-comfrey>. Published 2016. Accessed 5 June 2025. Last updated 21 August 2025
87. Seigner J, Junker-Samek M, Plaza A, et al. *Symphytum officinale* root extract exerts anti-inflammatory properties by affecting two distinct steps of NF- $\kappa$ B signaling. *Front Pharmacol.* 2019; 10(4):289.
88. Staiger C. Comfrey: A clinical overview. *Phytother Res.* 2012;26(10): 1441-1448.
89. Mei N, Guo L, Fu PP, et al. Metabolism, genotoxicity, and carcinogenicity of comfrey. *J. Toxicol. Environ. Health: Part B.* 2010; 13(7-8):509-526.
90. Stickel F, Seitz HK. The efficacy and safety of comfrey. *Public Health Nutr.* 2000; 3(4a):501-508.
91. Tai CJ, El-Shazly M, Wu TY. et al. Clinical aspects of *Aconitum* preparations. *Planta Medica.* 2015;81(12/13):1017-1028.
92. Nyirimigabo E, Xu Y, Li Y, et al. A review on phytochemistry, pharmacology and toxicology studies of *Aconitum*. *J Pharm Pharmacol.* 2015; 67(1):1-19.
93. Lawson C, McCabe DJ, Feldman R. A narrative review of aconite poisoning and management. *J Intensive Care Med.* 2024;40(8), pp.811-817.

94. Mountain Herb Estate Nursery. Plant Information. <https://www.herbgarden.co.za/mountainherb/herbinfo.php?id=35>. Accessed 14 June 2025
95. Sullivan JB, Rumack BH, Thomas H, et al. Pennyroyal oil poisoning and hepatotoxicity. *JAMA*. 1979. 242(26):2873-2874.
96. HealthLine. What is Chaparral, and is it safe? <https://www.healthline.com/nutrition/chaparral-herb>. Published 2020. Accessed 15 June 2025
97. Rodriguez-Fragoso L, Reyes-Esparza J, Burchiel SW, et al. Risks and benefits of commonly used herbal medicines in Mexico. *Toxicol Appl Pharmacol*. 2008; 227(1):125-135.
98. Arteaga S, Andrade-Cetto A, Cárdenas R. *Larrea tridentata* (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. *J of Ethnopharmacol*. 2005; 98(3):231-239.